Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB

Genes and Cancer

Volumn 7, Issue 9-10, 2016, Pages 278-287

  Hernández Monge, Jesús ^a   Rousset Roman, Adriana Berenice ^a   Medina Medina, Ixaura ^a   Olivares Illana, Vanesa ^a  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

Author keywords

MDM2; MDMX; P53; RB

Indexed keywords

CYCLIN A; CYCLIN D1; DOXORUBICIN; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P14; PROTEIN P53; TRANSCRIPTION FACTOR E2F1; UBIQUITIN PROTEIN LIGASE E3;

APOPTOSIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; DNA BINDING; DNA DAMAGE; ENZYME ACTIVITY; GENE INTERACTION; HUMAN; OSMOTIC STRESS; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RETINOBLASTOMA; REVIEW; UBIQUITINATION;

EID: 85027052256     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.18632/genesandcancer.120     Document Type: Review

References (92)

1. Olivares-Illana V, Fahraeus R. P53 isoforms gain functions. Oncogene. 2010;29:5113-5119.
2. Urso L, Calabrese F, Favaretto A, Conte P, Pasello G. Critical review about mdm2 in cancer: Possible role in malignant mesothelioma and implications for treatment. Crit Rev Oncol Hematol. 2016 Jan;97:220-30.
3. Pasello G, Urso L, Mencoboni M, Grosso F, Ceresoli GL, Lunardi F, Vuljan SE, Bertorelle R, Sacchetto V, Ciminale V, Rea F, Favaretto A, Conte P, Calabrese F. Mdm2 and hif1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: Correlation with pathological and clinical data. Oncotarget. 2015;6:42053-42066.
4. Zhao Y, Yu H, Hu W. The regulation of mdm2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin (Shanghai). 2014;46:180-189.
5. Zhang, Wang H. Mdm2 oncogene as a novel target for human cancer therapy. Curr Pharm Des. 2000;6:393-416.
6. Marine JC. Mdm2 and mdmx in cancer and development. Curr Top Dev Biol. 2011;94:45-75.
7. Berberich SJ. Mdm2 and mdmx involvement in human cancer. Subcell Biochem. 2014;85:263-280.
8. Naski N, Gajjar M, Bourougaa K, Malbert-Colas L, Fahraeus R, Candeias MM. The p53 mrna-mdm2 interaction. Cell Cycle. 2009;8:31-34.
9. Gajjar M, Candeias MM, Malbert-Colas L, Mazars A, Fujita J, Olivares-Illana V, Fahraeus R. The p53 mrna-mdm2 interaction controls mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell. 2012;21:25-35.
10. Malbert-Colas L, Ponnuswamy A, Olivares-Illana V, Tournillon AS, Naski N, Fahraeus R. Hdmx folds the nascent p53 mrna following activation by the atm kinase. Mol Cell. 2014;54:500-511.
11. Candeias MM, Malbert-Colas L, Powell DJ, Daskalogianni C, Maslon MM, Naski N, Bourougaa K, Calvo F, Fahraeus R. P53 mrna controls p53 activity by managing mdm2 functions. Nat Cell Biol. 2008;10:1098-1105.
12. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-330.
13. Ferreira R, Naguibneva I, Pritchard LL, Ait-Si-Ali S, Harel-Bellan A. The rb/chromatin connection and epigenetic control: Opinion. Oncogene. 2001;20:3128-3133.
14. Hilgendorf KI, Leshchiner ES, Nedelcu S, Maynard MA, Calo E, Ianari A, Walensky LD, Lees JA. The retinoblastoma protein induces apoptosis directly at the mitochondria. Genes Dev. 2013;27:1003-1015.
15. Sahi H, Savola S, Sihto H, Koljonen V, Bohling T, Knuutila S. Rb1 gene in merkel cell carcinoma: Hypermethylation in all tumors and concurrent heterozygous deletions in the polyomavirus-negative subgroup. APMIS. 2014;122:1157-1166.
16. Ohtani-Fujita N, Dryja TP, Rapaport JM, Fujita T, Matsumura S, Ozasa K, Watanabe Y, Hayashi K, Maeda K, Kinoshita S, Matsumura T, Ohnishi Y, Hotta Y, et al. Hypermethylation in the retinoblastoma gene is associated with unilateral, sporadic retinoblastoma. Cancer Genet Cytogenet. 1997;98:43-49.
17. Polager S, Ginsberg D. P53 and e2f: Partners in life and death. Nat Rev Cancer. 2009;9:738-748.
18. Rubin SM. Deciphering the retinoblastoma protein phosphorylation code. Trends Biochem Sci. 2013;38:12-19.
19. Sengupta S, Henry RW. Regulation of the retinoblastoma-e2f pathway by the ubiquitin-proteasome system. Biochim Biophys Acta. 2015;1849:1289-1297.
20. Wang Y, Zheng Z, Zhang J, Wang Y, Kong R, Liu J, Zhang Y, Deng H, Du X, Ke Y. A novel retinoblastoma protein (rb) e3 ubiquitin ligase (nrbe3) promotes rb degradation and is transcriptionally regulated by e2f1 transcription factor. J Biol Chem. 2015;290:28200-28213.
21. Ying H, Xiao ZX. Targeting retinoblastoma protein for degradation by proteasomes. Cell Cycle. 2006;5:506-508.
22. Knight JS, Sharma N, Robertson ES. Epstein-barr virus latent antigen 3c can mediate the degradation of the retinoblastoma protein through an scf cellular ubiquitin ligase. Proc Natl Acad Sci U S A. 2005;102:18562-18566.
23. Huh K, Zhou X, Hayakawa H, Cho JY, Libermann TA, Jin J, Harper JW, Munger K. Human papillomavirus type 16 e7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol. 2007;81:9737-9747.
24. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL. Dual-site regulation of mdm2 e3-ubiquitin ligase activity. Mol Cell. 2006;23:251-263.
25. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with mdm2;--fine mapping of the mdm2 binding site on p53 using synthetic peptides. Oncogene. 1994;9:2523-2529.
26. Yu GW, Rudiger S, Veprintsev D, Freund S, Fernandez-Fernandez MR, Fersht AR. The central region of hdm2 provides a second binding site for p53. Proc Natl Acad Sci U S A. 2006;103:1227-1232.
27. Honda R, Yasuda H. Activity of mdm2, a ubiquitin ligase, toward p53 or itself is dependent on the ring finger domain of the ligase. Oncogene. 2000;19:1473-1476.
28. Honda R, Tanaka H, Yasuda H. Oncoprotein mdm2 is a ubiquitin ligase e3 for tumor suppressor p53. FEBS Lett. 1997;420:25-27.
29. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM. Interaction between the retinoblastoma protein and the oncoprotein mdm2. Nature. 1995;375:694-698.
30. Sdek P, Ying H, Zheng H, Margulis A, Tang X, Tian K, Xiao ZX. The central acidic domain of mdm2 is critical in inhibition of retinoblastoma-mediated suppression of e2f and cell growth. J Biol Chem. 2004;279:53317-53322.
31. Lee C, Chang JH, Lee HS, Cho Y. Structural basis for the recognition of the e2f transactivation domain by the retinoblastoma tumor suppressor. Genes Dev. 2002;16:3199-3212.
32. Uchida C, Miwa S, Kitagawa K, Hattori T, Isobe T, Otani S, Oda T, Sugimura H, Kamijo T, Ookawa K, Yasuda H, Kitagawa M. Enhanced mdm2 activity inhibits prb function via ubiquitin-dependent degradation. EMBO J. 2005;24:160-169.
33. Zhang Y, Xiong Y, Yarbrough WG. Arf promotes mdm2 degradation and stabilizes p53: Arf-ink4a locus deletion impairs both the rb and p53 tumor suppression pathways. Cell. 1998;92:725-734.
34. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human cdkn2a locus, p14(arf), participates in a regulatory feedback loop with p53 and mdm2. EMBO J. 1998;17:5001-5014.
35. Sdek P, Ying H, Chang DL, Qiu W, Zheng H, Touitou R, Allday MJ, Xiao ZX. Mdm2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell. 2005;20:699-708.
36. Amador V, Ge S, Santamaria PG, Guardavaccaro D, Pagano M. Apc/c(cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell. 2007;27:462-473.
37. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, Hershko A. Role of the scfskp2 ubiquitin ligase in the degradation of p21cip1 in s phase. J Biol Chem. 2003;278:25752-25757.
38. Jin Y, Lee H, Zeng SX, Dai MS, Lu H. Mdm2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J. 2003;22:6365-6377.
39. Kim Y, Starostina NG, Kipreos ET. The crl4cdt2 ubiquitin ligase targets the degradation of p21cip1 to control replication licensing. Genes Dev. 2008;22:2507-2519.
40. Tsvetkov P, Reuven N, Shaul Y. Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ. 2010;17:103-108.
41. Chao CC. Mechanisms of p53 degradation. Clin Chim Acta. 2015;438:139-147.
42. Hsieh JK, Chan FS, O’Connor DJ, Mittnacht S, Zhong S, Lu X. Rb regulates the stability and the apoptotic function of p53 via mdm2. Mol Cell. 1999;3:181-193.
43. Delston RB, Matatall KA, Sun Y, Onken MD, Harbour JW. P38 phosphorylates rb on ser567 by a novel, cell cycle-independent mechanism that triggers rb-hdm2 interaction and apoptosis. Oncogene. 2011;30:588-599.
44. Raman M, Earnest S, Zhang K, Zhao Y, Cobb MH. Tao kinases mediate activation of p38 in response to DNA damage. EMBO J. 2007;26:2005-2014.
45. Yap DB, Hsieh JK, Chan FS, Lu X. Mdm2: A bridge over the two tumour suppressors, p53 and rb. Oncogene. 1999;18:7681-7689.
46. Stad R, Little NA, Xirodimas DP, Frenk R, van der Eb AJ, Lane DP, Saville MK, Jochemsen AG. Mdmx stabilizes p53 and mdm2 via two distinct mechanisms. EMBO Rep. 2001;2:1029-1034.
47. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van Oordt W, Hateboer G, van der Eb AJ, Jochemsen AG. Mdmx: A novel p53-binding protein with some functional properties of mdm2. EMBO J. 1996;15:5349-5357.
48. Sharp DA, Kratowicz SA, Sank MJ, George DL. Stabilization of the mdm2 oncoprotein by interaction with the structurally related mdmx protein. J Biol Chem. 1999;274:38189-38196.
49. Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G, Yuan ZM. Mutual dependence of mdm2 and mdmx in their functional inactivation of p53. J Biol Chem. 2002;277:19251-19254.
50. Wang X, Wang J, Jiang X. Mdmx protein is essential for mdm2 protein-mediated p53 polyubiquitination. J Biol Chem. 2011;286:23725-23734.
51. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL. Structure of the mdm2/mdmx ring domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 2008;15:841-848.
52. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M. Mdm2 interacts with mdmx through their ring finger domains. FEBS Lett. 1999;447:5-9.
53. Medina-Medina I, Garcia-Beltran P, de la Mora-de la Mora I, Oria-Hernandez J, Millot G, Fahraeus R, Reyes-Vivas H, Sampedro JG, Olivares-Illana V. Allosteric interactions by p53 mrna governs hdm2 e3 ubiquitin ligase specificity under different conditions. Mol Cell Biol. 2016
54. Uchida C, Miwa S, Isobe T, Kitagawa K, Hattori T, Oda T, Yasuda H, Kitagawa M. Effects of mdmx on mdm2-mediated downregulation of prb. FEBS Lett. 2006;580:1753-1758.
55. Zhang H, Hu L, Qiu W, Deng T, Zhang Y, Bergholz J, Xiao ZX. Mdmx exerts its oncogenic activity via suppression of retinoblastoma protein. Oncogene. 2015;34:5560-5569.
56. Hu L, Zhang H, Bergholz J, Sun S, Xiao ZX. Mdm2/mdmx: Master negative regulators for p53 and rb. Mol Cell Oncol. 2016;3:e1106635.
57. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789-799.
58. Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Lokkevik E, et al. Concomitant inactivation of the p53-and prb-functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. Mol Oncol. 2015;9:1553-1564.
59. Hashiguchi Y, Tsuda H, Yamamoto K, Inoue T, Ishiko O, Ogita S. Combined analysis of p53 and rb pathways in epithelial ovarian cancer. Hum Pathol. 2001;32:988-996.
60. Udayakumar T, Shareef MM, Diaz DA, Ahmed MM, Pollack A. The e2f1/rb and p53/mdm2 pathways in DNA repair and apoptosis: Understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Semin Radiat Oncol. 2010;20:258-266.
61. Brantley MA, Jr., Harbour JW. Deregulation of the rb and p53 pathways in uveal melanoma. Am J Pathol. 2000;157:1795-1801.
62. Venneti S, Le P, Martinez D, Eaton KW, Shyam N, Jordan-Sciutto KL, Pawel B, Biegel JA, Judkins AR. P16ink4a and p14arf tumor suppressor pathways are deregulated in malignant rhabdoid tumors. J Neuropathol Exp Neurol. 2011;70:596-609.
63. Ayrault O, Zindy F, Roussel MF. [tp53 and rb tumor suppressor pathways collaborate in retinoblastoma genesis]. Med Sci (Paris). 2007;23:356-358.
64. Knudsen ES, McClendon AK, Franco J, Ertel A, Fortina P, Witkiewicz AK. Rb loss contributes to aggressive tumor phenotypes in myc-driven triple negative breast cancer. Cell Cycle. 2015;14:109-122.
65. Ortega S, Malumbres M, Barbacid M. Cyclin d-dependent kinases, ink4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87.
66. Choi YJ, Anders L. Signaling through cyclin d-dependent kinases. Oncogene. 2014;33:1890-1903.
67. Guo Y, Pajovic S, Gallie BL: Expression of p14arf, mdm2, and mdm4 in human retinoblastoma. Biochem Biophys Res Commun. 2008;375:1-5.
68. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, et al. Inactivation of the p53pathway in retinoblastoma. Nature. 2006;444:61-66.
69. Laurie NA, Shih CS, Dyer MA. Targeting mdm2 and mdmx in retinoblastoma. Curr Cancer Drug Targets. 2007;7:689-695.
70. McEvoy J, Ulyanov A, Brennan R, Wu G, Pounds S, Zhang J, Dyer MA. Analysis of mdm2 and mdm4 single nucleotide polymorphisms, mrna splicing and protein expression in retinoblastoma. PLoS One. 2012;7:e42739.
71. Xing EP, Nie Y, Song Y, Yang GY, Cai YC, Wang LD, Yang CS. Mechanisms of inactivation of p14arf, p15ink4b, and p16ink4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res. 1999;5:2704-2713.
72. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B. 14-3-3 sigma is a p53-regulated inhibitor of g2/m progression. Mol Cell. 1997;1:3-11.
73. Mlynarczyk C, Fahraeus R: Endoplasmic reticulum stress sensitizes cells to DNA damage-induced apoptosis through p53-dependent suppression of p21(cdkn1a). Nat Commun. 2014;5:5067.
74. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010-1014.
75. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T. Stimulation of e2f1/dp1 transcriptional activity by mdm2 oncoprotein. Nature. 1995;375:691-694.
76. Zhang Z, Wang H, Li M, Rayburn ER, Agrawal S, Zhang R. Stabilization of e2f1 protein by mdm2 through the e2f1 ubiquitination pathway. Oncogene 2005;24:7238-7247.
77. Tian X, Chen Y, Hu W, Wu M. E2f1 inhibits mdm2 expression in a p53-dependent manner. Cell Signal. 2011;23:193-200.
78. Strachan GD, Jordan-Sciutto KL, Rallapalli R, Tuan RS, Hall DJ: The e2f-1 transcription factor is negatively regulated by its interaction with the mdmx protein. J Cell Biochem. 2003;88:557-568.
79. Wunderlich M, Ghosh M, Weghorst K, Berberich SJ. Mdmx represses e2f1 transactivation. Cell Cycle. 2004;3:472-478.
80. Strachan GD, Rallapalli R, Pucci B, Lafond TP, Hall DJ: A transcriptionally inactive e2f-1 targets the mdm family of proteins for proteolytic degradation. J Biol Chem. 2001;276:45677-45685.
81. O’Connor DJ, Lam EW, Griffin S, Zhong S, Leighton LC, Burbidge SA, Lu X. Physical and functional interactions between p53 and cell cycle co-operating transcription factors, e2f1 and dp1. EMBO J. 1995;14:6184-6192.
82. Taura M, Suico MA, Fukuda R, Koga T, Shuto T, Sato T, Morino-Koga S, Okada S, Kai H. Mef/elf4 transactivation by e2f1 is inhibited by p53. Nucleic Acids Res. 2011;39:76-88.
83. Hsieh JK, Yap D, O’Connor DJ, Fogal V, Fallis L, Chan F, Zhong S, Lu X. Novel function of the cyclin a binding site of e2f in regulating p53-induced apoptosis in response to DNA damage. Mol Cell Biol. 2002;22:78-93.
84. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992;358:80-83.
85. Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, Wahl GM. A mouse p53 mutant lacking the proline-rich domain rescues mdm4 deficiency and provides insight into the mdm2-mdm4-p53 regulatory network. Cancer Cell. 2006;9:273-285.
86. Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, Li KC, Hong TM, Yang PC. P53 controls cancer cell invasion by inducing the mdm2-mediated degradation of slug. Nat Cell Biol. 2009;11:694-704.
87. Wade M, Wang YV, Wahl GM: The p53 orchestra: Mdm2 and mdmx set the tone. Trends Cell Biol. 2010;20:299-309.
88. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, Schlegel U, Reifenberger G. Amplification and overexpression of the mdm4 (mdmx) gene from 1q32 in a subset of malignant gliomas without tp53 mutation or mdm2 amplification. Cancer Res. 1999;59:6091-6096.
89. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237-1245.
90. Shimizu H, Burch LR, Smith AJ, Dornan D, Wallace M, Ball KL, Hupp TR. The conformationally flexible s9-s10 linker region in the core domain of p53 contains a novel mdm2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem. 2002;277:28446-28458.
91. Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD, Wang CY, Zambrowicz BP, Ramirez-Solis R, Sands AT, Zhang N. Mdmx is a negative regulator of p53 activity in vivo. Cancer Res. 2002;62:3221-3225.
92. Wei X, Wu S, Song T, Chen L, Gao M, Borcherds W, Daughdrill GW, Chen J. Secondary interaction between mdmx and p53 core domain inhibits p53 DNA binding. Proc Natl Acad Sci U S A. 2016;113:E2558-2563.